USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024
Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies
24-Jul-2020
North America
Market Research
MEAA-01-00-00-00
HC03303-GL-MT_24493
$4,950.00
Special Price $3,712.50 save 25 %
With this research service, Frost & Sullivan’s Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.
This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, Frost & Sullivan’s group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.
Research Highlights
Highlights of the report include:
- Market revenue forecast for the global biologics market till 2024
- Segment-wise revenue forecast of the top market players and key therapeutic areas
- Top 3 predictions for the global biologics market
- Technology trends influencing the future outlook of the biologics market
- Growth opportunities in the global biologics market
- Strategic recommendations for the biologics market
- COVID-19 impact analysis on the biologics market
Key Issues Addressed
- What will be the revenue and growth rate for the global biologics market from 2020 to 2024?
- What will be the major segments influencing this revenue and growth rate?
- What are the key technologies and trends to watch for during the forecast period?
- What are the major growth opportunities in the biologics industry?
- What are the top predictions for the biologics market?
Purpose of this Study
Methodology
5-step Process to Transformational Growth
Key Findings
Key Questions this Study will Answer
Market Engineering Measurements
Transformation in the Industry Ecosystem
Macro Trends—Biologics Discovery, Development and Manufacturing
Technology Trends—Biologics Discovery, Development and Manufacturing
5 Big Themes for the Global Biologics Market
Strategic Imperatives for the Biologics Market
Scope
Market Segmentation
Description of Main Product Categories
Characteristics of Biologics
Lifecycle of Biologics Products
Market Drivers and Restraints
Key Biologics Companies
Biologics R&D Expenditure
Regulatory Framework for Biologics Approval
Region-wise Regulatory Drug Approval Trends
Key Issues in Market Entry for Regenerative Medicine
Top-level Impact of COVID-19 Pandemic on the Biologics Market
Biologics Manufacturing and Supply Line Challenges
Biologics Pipeline Targeting COVID-19 (SARS-COV-2)
Revenue Forecast—COVID-19 Impact Methodology
Growth Opportunities Critical for Future Success in a Post-pandemic Biologics Market
Companies to Action
Strategic Imperatives for Companies in Light of COVID-19
Methodology
Market Engineering Measurements
Revenue Forecast—Pre-COVID-19 vs. Post-COVID-19 Impact
Product Segmentation
Total Biologics Market—Top 10 Products
Breakdown by Therapeutic Area
Changing Dynamics
Percent Revenue Forecast by Product Type
Antibody Therapies—Overview of Top 10 Products
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Anticipated Key Product Launches
Changing Dynamics
Technology Trends in the Antibody Therapy Platform
Recombinant Proteins—Overview of Top 10 Products
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Anticipated Key Product Launches
Changing Dynamics
Vaccines—Overview of Top 10 Products
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Anticipated Key Product Launches
Changing Dynamics
Cell & Gene Therapy—Overview of Top 10 Products
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Technology Trends in the Cell Therapy Platform
Anticipated Key Product Launches
Changing Dynamics
Technology Trends in RNA and Viral Vector Platforms
Roche AG
AMGEN
Sanofi
AbbVie
Novo Nordisk
Merck
Pfizer
Johnson & Johnson
Eli Lilly
GlaxoSmithKline
Major Growth Opportunities
Growth Opportunity 1—ADCs/Polyclonal Antibodies
The Future Trends in Antibody Therapy
ADC Pipeline Analysis
ADCs—Need for Outsourcing
Bio-CDMO Benchmarking—ADC Development and Manufacturing Services
Growth Opportunity 2—RNA-based Therapies & Vaccines
Strategic Imperatives for Better Vaccines
RNA Therapy Pipeline Analysis and Industry Partnerships
mRNA Technology set to Revolutionize Vaccine Therapies
Growth Opportunity 3—Gene Therapy Advancements
Investments & Partnerships Advancing CRISPR/Cas Gene Editing Technology
Gene Therapy—Collaborations and Partnerships
CDMOs to Drive the Growth of Gene Therapy
Growth Opportunity Matrix
Top 3 Predictions for the Market
Legal Disclaimer
Market Engineering Methodology
List of Key Companies Included in this Research Service
List of Exhibits
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
Highlights of the report include:
- Market revenue forecast for the global biologics market till 2024
- Segment-wise revenue forecast of the top market players and key therapeutic areas
- Top 3 predictions for the global biologics market
- Technology trends influencing the future outlook of the biologics market
- Growth opportunities in the global biologics market
- Strategic recommendations for the biologics market
- COVID-19 impact analysis on the biologics market
Key Issues Addressed
- What will be the revenue and growth rate for the global biologics market from 2020 to 2024?
- What will be the major segments influencing this revenue and growth rate?
- What are the key technologies and trends to watch for during the forecast period?
- What are the major growth opportunities in the biologics industry?
- What are the top predictions for the biologics market?
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Deepak Jayakumar |
| Industries | Healthcare |
| WIP Number | MEAA-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1 |